Market capitalization | $117.38m |
Enterprise Value | $57.04m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.12 |
P/S ratio (TTM) P/S ratio | 4.37 |
P/B ratio (TTM) P/B ratio | 3.80 |
Revenue growth (TTM) Revenue growth | -42.35% |
Revenue (TTM) Revenue | $26.87m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
6 Analysts have issued a Innate Pharma - ADR forecast:
6 Analysts have issued a Innate Pharma - ADR forecast:
Jun '24 |
+/-
%
|
||
Revenue | 27 27 |
42%
42%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -49 -49 |
70%
70%
|
EBIT (Operating Income) EBIT | -51 -51 |
47%
47%
|
Net Profit | -37 -37 |
42%
42%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells. The company was founded by Hervé Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié and François Romagné on September 15, 1999 and is headquartered in Marseille, France.
Head office | France |
CEO | Jonathan Dickinson |
Employees | 179 |
Founded | 1999 |
Website | www.innate-pharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.